Viridian reports positive phase 3 data for veligrotug in TED; cash $717.6M

Viridian Therapeutics, Inc.\DE

Veligrotug met all primary and secondary endpoints in THRIVE and THRIVE-2 for active and chronic TED.
BLA submission on track for 2H 2025; MAA submission expected 1H 2026.
Cash, equivalents, and investments $717.6M as of Dec 31, 2024, funding operations into 2H 2027.
Net loss $269.9M for 2024 vs $237.7M in 2023; R&D expenses rose to $238.3M.
Appointed Radhika Tripuraneni as CMO, succeeding Thomas Ciulla who transitions to consultant.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.